Outlook Therapeutics, Inc. (OTLK) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 95 transactions totaling $35.0M, demonstrating a bullish sentiment with $32.1M in net insider flow. The most recent transaction on Sep 26, 2024 involved a purchase of 5,000 shares valued at $28.4K.
No significant insider buying has been recorded for OTLK in the recent period.
No significant insider selling has been recorded for OTLK in the recent period.
Based on recent SEC filings, insider sentiment for OTLK is bullish with an Insider Alignment Score of 96/100 and a net flow of $32.1M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Outlook Therapeutics, Inc. (OTLK) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading OTLK stock, having executed 95 transactions in the past 90 days. The most active insider is Ghiath M. Sukhtian (Executive), who has made 8 transactions totaling $47.1M.
Get notified when executives and directors at OTLK file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 26, 2024 | A. Kenyon Lawrence | Executive | Purchase | 5,000 | $5.69 | $28.4K | |
| Apr 15, 2024 | Llc Syntone Ventures | Executive | Purchase | 714,286 | $N/A | $0 | |
| Mar 28, 2024 | Munther Haddadin Yezan | Executive | Purchase | 1,881.71 | $11.82 | $22.2K | |
| Mar 18, 2024 | M. Sukhtian Ghiath | Executive | Award | 2,305,714 | $N/A | $0 | |
| Mar 7, 2024 | Evanson Jeff | Executive | Purchase | 62,484 | $0.42 | $26.2K | |
| Apr 20, 2023 | Dagnon Terry | Executive | Sale | 520,000 | $1.14 | $592.8K | Large |
| Jan 20, 2023 | Evanson Jeff | Executive | Sale | 267,000 | $1.11 | $296.4K | |
| Jan 19, 2023 | Evanson Jeff | Executive | Sale | 103,255 | $1.22 | $126.0K | |
| Jan 18, 2023 | Evanson Jeff | Executive | Sale | 33,738 | $1.25 | $42.2K | |
| Jan 17, 2023 | Evanson Jeff | Executive | Sale | 27,162 | $1.31 | $35.6K | |
| Dec 28, 2022 | M. Sukhtian Ghiath | Executive | Award | 14,230,418 | $0.88 | $12.5M | Large |
| Oct 7, 2022 | Munther Haddadin Yezan | Executive | Purchase | 3,600 | $1.27 | $4.6K | |
| Oct 7, 2022 | Ghiath Sukhtian Faisal | Executive | Purchase | 30,000 | $1.29 | $38.7K | |
| Oct 6, 2022 | Munther Haddadin Yezan | Executive | Purchase | 29,743 | $1.29 | $38.4K | |
| Oct 5, 2022 | J. Hilzinger Kurt | Executive | Purchase | 15,662 | $1.23 | $19.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 10 | $38.0M | 46.9% |
Purchase(P) | 65 | $33.6M | 41.4% |
Other(J) | 5 | $6.3M | 7.7% |
Exercise(M) | 4 | $1.7M | 2.1% |
Sale(S) | 11 | $1.5M | 1.8% |
Insiders at Outlook Therapeutics, Inc. are accumulating shares at an accelerated pace. With 14 insiders making 95 transactions totaling $33.6M in purchases versus $1.5M in sales, the net buying activity of $32.1M signals strong executive confidence. Ghiath M. Sukhtian (Executive) leads the buying activity with $47.1M in transactions across all time.